MHRA approves UK’s first new type of antibiotic for urinary tract infections

As with any medicine, the MHRA will keep the safety of gepotidacin under close review

Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections

The approval marks a major milestone in the global fight against antimicrobial resistance

Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%

US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya

AKUMS launches Aztreonam-Avibactam injection to combat multidrug-resistant infections

The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand

Wockhardt’s breakthrough antibiotic Zaynich wins key regulatory nod in India

Alembic enters US branded market with first sales of Pivya UTI treatment

Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC

Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia

Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination

Wockhardt’s WCK 5222 earns accelerated review from European Medicines Agency

The accelerated review covers WCK 5222 for multiple critical infections

MHRA clears inavolisib, offering new option for returning breast cancer

The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy

Wockhardt submits NDA to USFDA for Zidebactam-Cefepime injection

The NDA submission follows the successful completion of a pivotal Phase III global clinical trial